Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. Show more
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2514 | -30.6585365854 | 0.82 | 0.83 | 0.5605 | 158530 | 0.76069403 | CS |
4 | -0.0023 | -0.402872657208 | 0.5709 | 1.1099 | 0.54 | 734269 | 0.88108417 | CS |
12 | -0.3364 | -37.1712707182 | 0.905 | 1.1099 | 0.5 | 249581 | 0.8778708 | CS |
26 | -0.7514 | -56.9242424242 | 1.32 | 1.87 | 0.5 | 121162 | 0.91969782 | CS |
52 | -1.3014 | -69.5935828877 | 1.87 | 1.98 | 0.5 | 66692 | 0.92915294 | CS |
156 | -6.8714 | -92.3575268817 | 7.44 | 9.4 | 0.5 | 65250 | 4.02415015 | CS |
260 | -14.3914 | -96.199197861 | 14.96 | 19.56 | 0.5 | 352516 | 10.82740288 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.